PHILADELPHIA – June 4, 2015 ––ERT, a leading global provider of high-quality patient safety and efficacy endpoint data collection, cloud analytics and workflow solutions, today announced the availability of a new solution to wirelessly integrate ECG data collection with an electronic Clinical Outcome Assessments (eCOA) tablet – reducing site burden while improving data quality in clinical research. With the wireless ECG / eCOA tablet solution, a small, lightweight, wireless ECG device is unified with a tablet, which streamlines data collection, eases burden on investigative site staff and improves data quality with real-time data capture. Leveraging the integrated solution, clinical researchers collect vital, objective cardiac safety endpoint data along with patient and clinician reported outcome data, resulting in a more comprehensive view into patient health and well-being.
ERT’s wireless ECG / eCOA tablet solution is shipped to investigative sites preconfigured for data collection and ready for immediate use. During site visits, patient ECG and eCOA data are collected and automatically transmitted to the ERT Insights Cloud™, a private clinical research system accessible to qualified study personnel in real-timeonline. This robust, secure and validated clinical research workflow simplifies electronic data collection, data management and information exchange, dramatically reducing both site workload and the volume of queries generated.
“Cardiac safety continues to be the primary reason for drug withdrawals,” explained Amy Furlong, Executive Vice President, Cardiac Safety and eClinical Insights Solutions, ERT. “Our mobile, integrated ECG / eCOA tablet solution provides a single point of collection to optimize digital data quality and reduce burden for both clinical sites and sponsors.”
ERT continuously innovates to optimize the clinical research process in order to bring drug therapies to market faster and at a reduced cost. The global company is committed to expanding its current offering of integrated medical devices and wearables such as spirometers, glucose meters, blood pressure monitors, activity patches/meters and other devices to collect endpoints of import. ERT is bringing data collection to the patient by integrating individual Internet of Things (IoT) with electronic clinical outcome assessments, thereby increasing patient data values. By reimagining data management to deliver critical missing insights on clinical research for biopharmaceutical companies and CROs of every size at every stage in the drug development process, ERT innovates better health every day.
More information on the wireless ECG / eCOA integration and the Insights Cloud will be reviewed during a complimentary webinar on June 11, 2015. Register at http://www.ert.com/upcoming-webinars to participate in “Reducing Site Burden and Automating Real-Time Data Delivery: eCOA, ECG & EDC Integration.”
ERT will also demonstrate the new solution and many others at the ERT Innovation Lab Booth #2000 and also at the expanded ERT Booth #2025 during the Drug Information Association (DIA) Annual Meeting in Washington, DC beginning June 15, 2015. Additional information is available at http://www.ert.com/ecg-ecoa-tablet.
Using Patient Reported Outcomes in Dermatology Trials
April 25th 2024In part 3 of this video interview with ACT editor Andy Studna, Melissa Mooney, director, eCOA sales engineering, IQVIA sheds light on the unique challenges of dermatology trials and how clinical outcome assessments can be implemented in them.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
FDA Grants Ziftomenib with Breakthrough Therapy Designation for NPM1-Mutant Acute Myeloid Leukemia
April 23rd 2024Data from the Phase Ib portion of the KOMET-001 trial showed that the once-daily oral treatment may provide a substantial improvement over available therapies for relapsed/refractory NPM1-mutant acute myeloid leukemia.